1. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). (September 2016) Authors: Ravandi, Farhad; Gojo, Ivana; Patnaik, Mrinal M.; Minden, Mark D.; Kantarjian, Hagop; Johnson-Levonas, Amy O.; Fancourt, Craig; Lam, Raymond; Jones, Mary Beth; Knox, Clayton D.; Rose, Shelonitda; Patel, Payal Shah; Tibes, Raoul Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). (September 2016) Authors: Ravandi, Farhad; Gojo, Ivana; Patnaik, Mrinal M.; Minden, Mark D.; Kantarjian, Hagop; Johnson-Levonas, Amy O.; Fancourt, Craig; Lam, Raymond; Jones, Mary Beth; Knox, Clayton D.; Rose, Shelonitda; Patel, Payal Shah; Tibes, Raoul Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. (October 2016) Authors: Michot, Jean-Marie; Mazeron, Renaud; Dercle, Laurent; Ammari, Samy; Canova, Charles; Marabelle, Aurelien; Rose, Shelonitda; Rubin, Eric; Deutsch, Eric; Soria, Jean-Charles; Ribrag, Vincent; Levy, Antonin Journal: European journal of cancer Issue: Volume 66(2016) Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. Issue 5 (29th May 2021) Authors: Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Jourdan, Eric; Silver, Richard T.; Schouten, Harry C.; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Tang, Derek; Abraham, Pranav; Lord-Bessen, Jennifer; Rose, Shelonitda; Guo, Sh... Journal: HemaSphere Issue: Volume 5:Issue 5(2021) Page Start: e562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Issue 6 (17th April 2020) Authors: Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean‐Jacques; Jourdan, Eric; Silver, Richard T.; Schouten, Harry C.; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Shen, Juan; Berry, Tymara; Brownstein, Carrie; Mesa, Ruben A. Journal: American journal of hematology Issue: Volume 95:Issue 6(2020:Jun.) Page Start: 594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Issue 5 (29th May 2021) Authors: Mesa, Ruben A.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Abraham, Pranav; Lord-Bessen, Jennifer; Tang, Derek; Guo, Shien; Ye, Xiaomei; Harrison, Claire N. Journal: HemaSphere Issue: Volume 5:Issue 5(2021) Page Start: e553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. (27th April 2022) Authors: Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean‐Jacques; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Zhang, Jun; Sy, Oumar; Mesa, Ruben A. Journal: British journal of haematology Issue: Volume 198:Number 2(2022) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. (30th July 2021) Authors: Pardanani, Animesh; Tefferi, Ayalew; Masszi, Tamás; Mishchenko, Elena; Drummond, Mark; Jourdan, Eric; Vannucchi, Alessandro; Jurgutis, Mindaugas; Ribrag, Vincent; Rambaldi, Alessandro; Koh, Liang Piu; Rose, Shelonitda; Zhang, Jun; Harrison, Claire Journal: British journal of haematology Issue: Volume 195:Number 2(2021) Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗